List of Drospirenone drug patents

Drospirenone is owned by Exeltis Usa Inc.

Drospirenone contains Drospirenone.

Drospirenone has a total of 13 drug patents out of which 0 drug patents have expired.

Drospirenone was authorised for market use on 29 June, 2022.

Drospirenone is available in tablet, chewable;oral dosage forms.

Drospirenone can be used as prevention of pregnancy in females of reproductive age.

The generics of Drospirenone are possible to be released after 28 June, 2031.

DROSPIRENONE's oppositions filed in EPO
Can you believe DROSPIRENONE received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10603281 EXELTIS USA INC Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Jun, 2031

(8 years from now)

US10849857 EXELTIS USA INC Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Jun, 2031

(8 years from now)

US9603860 EXELTIS USA INC Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Jun, 2031

(8 years from now)

US10179140 EXELTIS USA INC Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Jun, 2031

(8 years from now)

US11413249 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(8 years from now)

US10987364 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(8 years from now)

US11351122 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(8 years from now)

US11291632 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(8 years from now)

US11291633 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(8 years from now)

US11123299 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(8 years from now)

US11439598 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(8 years from now)

US11478487 EXELTIS USA INC NA
Jun, 2031

(8 years from now)

US11504334 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(8 years from now)

Do you want to check out DROSPIRENONE patents from before 2022?
Exclusivity Exclusivity Expiration
New Product (NP) Jun 29, 2025

Drugs and Companies using DROSPIRENONE ingredient

Market Authorisation Date: 29 June, 2022

Treatment: Prevention of pregnancy in females of reproductive age

Dosage: TABLET, CHEWABLE;ORAL

More Information on Dosage

DROSPIRENONE family patents

19

United States

5

European Union

4

Korea, Republic of

4

Lithuania

4

Hungary

3

Canada

3

Guatemala

3

Mexico

3

Ecuador

2

Spain

2

Denmark

2

RS

2

Poland

2

Brazil

2

Croatia

2

Peru

2

Portugal

2

Slovenia

1

Argentina

EA

1

EA

1

Norway

1

Japan

1

New Zealand

1

Cyprus

1

Chile

1

Australia

1

South Africa

1

Colombia

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in